NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NEXGEL reported a 32% year-over-year revenue increase, reaching $2.05 million for 2022, driven by 34.7% growth in contract manufacturing and a 67.0% rise in branded consumer products. By year-end, the company had over $6.6 million in cash and securities, ensuring operational stability through 2025. Despite a slight revenue dip in Q4 2022, NEXGEL launched innovative products like Turfguard and expanded its joint ventures. The gross profit margin improved significantly to approximately 12.5%, a 3,100% increase from the previous year. However, a net loss of $4.75 million was reported for 2022, with expectations of reduced interest expenses in the coming year.